Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Short SellingSee which listed companies have disclosed short interest
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Revenio Q2'26 preview: First step for new vision

REG1VResearch31.08.2026 klo 10.25
Juha KinnunenAnalyst
Discuss
Download report (PDF)

Summary

  • The analyst reiterates a Buy recommendation and a EUR 20.0 target price for Revenio, anticipating the Q2 report to provide insights into the Visionix acquisition's impact on earnings and integration progress.
  • Revenio's Q2 revenue is expected to grow to approximately 41 MEUR, with Visionix contributing around 12 MEUR, deviating significantly from the consensus estimate of 29 MEUR.
  • Adjusted EBIT for Q2 is forecasted at 7.5 MEUR, with a margin over 18%, including 3 MEUR in one-off M&A costs, highlighting Visionix's minor yet positive role in the results.
  • The report is expected to offer preliminary guidance for 2026, with a focus on achieving synergies over 20 MEUR, and the valuation is seen as attractive despite uncertainties, with an adj. EV/EBITA of 13x based on the 2027 estimate.

This content is generated by AI. You can give feedback on it in the Inderes forum.

Translation: Original published in Finnish on 8/31/2026 at 8:00 am EEST.

We reiterate our Buy recommendation and EUR 20.0 target price for Revenio. Revenio will publish its quarterly report on Tuesday, September 8, which will also include a one-month contribution from the Visionix acquisition. We are looking to the report especially for visibility into the new entity: Visionix's current earnings performance, the initial steps of the integration, measures for the rest of the year, and the schedule of the upcoming rights issue. We consider it particularly essential to clarify the operational earnings performance and outlook amidst a major process. This will likely be made more concrete by the new guidance for the combined entity.  

Visionix consolidation causes significant deviation from consensus

We expect Revenio's revenue to have grown to around 41 MEUR in Q2 (Q2'25: 26.5 MEUR). We have included Visionix's June revenue in our estimates, assuming it was approximately 12 MEUR (which would correspond to an average month in 2025). This is subject to considerable uncertainty, as there is no information on Visionix's growth or seasonality. The consensus estimate for revenue is only 29 MEUR, which, in our view, does not include Visionix's revenue. This would mean revenue growth of about 9% for the "old Revenio", which we consider to be a realistic level.

We forecast adjusted EBIT to land at 7.5 MEUR in Q2 (Q2'25: 6.6 MEUR), which would translate to an adjusted EBIT margin of just over 18%. We forecast adjusted EBIT to land at 7.5 MEUR in Q2 (Q2'25: 6.6 MEUR), which would translate to an adjusted EBIT margin of just over 18%. In our forecast, Visionix's role remains minor, but it is nevertheless positive and explains the difference between our forecast and the consensus (adj. EBIT of 6.4 MEUR). In addition, our forecast includes 3 MEUR in one-off costs related to the M&A transaction, which weighs on the reported result. Overall, the Visionix acquisition and related integration costs are estimated to be 20 MEUR, but the share of costs to be booked in Q2 remains unclear.

We are looking to the report especially for future visibility

In the Q2 report, we are particularly looking for visibility into the new entity, where critical factors include Visionix's current earnings performance, the progress of the company's profitability program, the progress of integration and future measures, as well as the rights issue schedule. At the same time, we aim to determine the operational condition and outlook of the "old Revenio". Other important factors for earnings forecasts are the new PPA amortizations of intangible assets.

We expect Revenio to provide at least preliminary guidance for 2026 once the company has consolidated Visionix and formed a clearer view of the new entity's outlook. In our view, this is the most interesting single aspect of the report. We currently expect Revenio's revenue to be around 205 MEUR and its adjusted EBIT to be around 34 MEUR in 2026, against which the guidance can be mirrored. We believe that achieving the targeted synergies of over 20 MEUR is a prerequisite for value creation in the combined company. In this regard, we also hope to receive more information on the timing of the non-recurring expenses. 

Valuation will be recognized as outlook becomes clearer

Revenio's adj. EV/EBITA is 13x based on the 2027 estimate, which includes few synergies. If the company were to reach its targets in the Visionix acquisition in 2030, the EV/EBITDA multiple would be in the range of 4–5x. As integration progresses, a long period of uncertainty still lies ahead, but visibility will begin to gradually improve in the near future. Particularly after the rights offering, we expect uncertainty to decrease significantly. We acknowledge the uncertainty associated with our estimates, but we consider the risk/reward ratio of the stock to be exceptionally attractive.

Login required

This content is only available for logged in users

Create account

Revenio is a global provider of comprehensive eye care diagnostic solutions. The group offers fast, user-friendly, and reliable tools for diagnosing glaucoma, diabetic retinopathy, and macular degeneration (AMD). Revenio’s ophthalmic diagnostic solutions include intraocular pressure (IOP) measurement devices (tonometers), fundus imaging devices, and perimeters as well as software solutions under the iCare brand. In 2023, the Group’s net sales totaled EUR 96.6 million, with an operating profit of EUR 26.3 million. Revenio Group Corporation is listed on Nasdaq Helsinki with the trading code REG1V.

Read more on company page

Key Estimate Figures31.08.

202526e27e
Revenue109.7206.1278.6
growth-%6.0 %87.9 %35.1 %
EBIT (adj.)26.533.948.4
EBIT-% (adj.)24.2 %16.4 %17.4 %
EPS (adj.)0.700.830.88
Dividend0.000.000.00
Dividend %
P/E (adj.)27.718.016.9
EV/EBITDA16.722.211.1

Forum discussions

The ratio is likely around 4:1. This means you will receive one subscription right (merkintäoikeus) for every four shares. The subscription ...
1 hour ago
by JBulli
0
Here is Juha’s preliminary company report ahead of Revenio’s Q2 earnings release on Tuesday, September 8th We reiterate our buy recommendation...
2 hours ago
by Sijoittaja-alokas
4
The directed share issues related to the transaction have already been completed, and they have increased the number of shares to approximately...
18 hours ago
by Rellibs
5
The rights offering aims to raise 80 million from shareholders, and there are currently about 26.7 million shares. Thus, approximately 3 euros...
20 hours ago
6
I think I am in a situation with this stock for the 1st time where I have to/get to receive subscription rights (merkintäoikeudet) in connection...
20 hours ago
by Matsku
1
A small target price increase from Kauppalehti’s flash news: Danske Bank raises Revenio’s target price to €20.00 from €19.00 and reiterates ...
8/27/2026, 7:06 AM
by NukkeNukuttaja
16
So stories change. Nowadays, there is a strong belief in efficient markets, and every single thing is “priced in”. Benjamin Graham used to talk...
8/24/2026, 8:30 AM
by Ummon
32